HOME COMPANY TECHNOLOGY PATIENTS CLINICAL TRIAL MEDIA INVESTORS PROFESSIONALS CONTACT US Overview Evaluation Criteria Inclusion Criteria Participating Centers Testimonials Contact EVALUATION CRITERIA The principal evaluation criterion of the trial is the analysis of the incidence, severity and duration of all adverse effects after 3, 6, 12 and 18 months. The secondary evaluation criteria involve measuring visual perception to show the potential benefits of IRIS®. They are assessed by comparing the patients' capacity to carry out a visual task with and without the device (meaning the device is either on or off) 3, 6, 12 and 18 months after implantation. Initial performance (before implantation) is also determined. Twitter @PixiumVision Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles. Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles. COMPANY About Pixium Vision Management Board of Directors Scientific & Medical Commitee Partners TECHNOLOGY Technology Bionic VRS Technology Smart Bioinspired Neuromorphic (Event-Based) Camera IRIS® Bionic Vision Restoration System PRIMA Bionic Vision Restoration System PATIENTS Overview Blindness Retinitis Pigmentosa (RP) Age-related macular degeneration (AMD) Useful Links CLINICAL TRIAL Overview Evaluation Criteria Inclusion Criteria Participating Centers Testimonials Contact MEDIA Press Releases In the News Events Publications Press Kit INVESTORS Letter from the Chairman Share Information Press Releases Conferences Financial Reports and Documents Broker research Other Regulated Information Analyst Coverage Shareholder's General Meeting Financial Calendar Contact PROFESSIONALS Technology Indications Clinical trial CONTACT US Contact us Job opportunities © COPYRIGHT PIXIUM VISION. ALL RIGHTS RESERVED. | LEGAL INFORMATION | DESIGN : AGENCE K2